Print Save or Share

Dapagliflozin Approval Status beta

  • FDA approved: No
  • Generic name: dapagliflozin
  • Company: Bristol-Myers Squibb Company and AstraZeneca
  • Treatment for: Diabetes, Type 2

Dapagliflozin is an investigational selective sodium-glucose cotransporter-2 inhibitor for the treatment of adults with type 2 diabetes mellitus.

FDA Approval Status for dapagliflozin

DateArticle
Jan 19, 2012Bristol-Myers Squibb and AstraZeneca Receive Complete Response Letter from U.S. Food and Drug Administration for Dapagliflozin
Oct 27, 2011U.S. Food and Drug Administration Extends Action Date for Dapagliflozin by Three Months
Jul 20, 2011FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin
Mar  8, 2011FDA Accepts New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Advertisement
Close

Recommended

(web1)